"Gen-Probe's second quarter financial results demonstrate our ability to drive growth...]]> , July 29 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today reported financial results for the second quarter of 2010, highlighted by 14% growth in product sales, 15% growth in total revenues, and 16% growth in non-GAAP earnings per share (EPS).

"Gen-Probe's second quarter financial results demonstrate our ability to drive growth...]]> http://www.biospace.com/news_story.aspx?StoryID=189119&full=1/feed/ 0 http://www.biospace.com/news_story.aspx?StoryID=189121&full=1 http://www.biospace.com/news_story.aspx?StoryID=189121&full=1#comments Fri, 30 Jul 2010 00:00:00 +0000 BioSpace.com Featured News tag:feedrinse.com://a0f09c98f84e9b5b16d9bbef3ebe08e4 , July 29 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today reported revenue of $50.9 million for the second quarter of 2010. Net income was $5.6 million or $0.31 per diluted share for the quarter. ...]]> , July 29 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today reported revenue of $50.9 million for the second quarter of 2010. Net income was $5.6 million or $0.31 per diluted share for the quarter. ...]]> http://www.biospace.com/news_story.aspx?StoryID=189121&full=1/feed/ 0 http://www.biospace.com/news_story.aspx?StoryID=189137&full=1 http://www.biospace.com/news_story.aspx?StoryID=189137&full=1#comments Fri, 30 Jul 2010 00:00:00 +0000 BioSpace.com Featured News tag:feedrinse.com://9639721a0b1b38062d1a720d16be7252 , July 30/PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report second quarter 2010 financial results on Friday, August...]]> , July 30/PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report second quarter 2010 financial results on Friday, August...]]> http://www.biospace.com/news_story.aspx?StoryID=189137&full=1/feed/ 0 http://www.biospace.com/news_story.aspx?StoryID=189126&full=1 http://www.biospace.com/news_story.aspx?StoryID=189126&full=1#comments Fri, 30 Jul 2010 00:00:00 +0000 BioSpace.com Featured News tag:feedrinse.com://271bfd0bf4892222b60f79756747b328 , July 29 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), will report second quarter 2010 financial results after market close on Thursday August 5, 2010. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time...]]> , July 29 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), will report second quarter 2010 financial results after market close on Thursday August 5, 2010. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time...]]> http://www.biospace.com/news_story.aspx?StoryID=189126&full=1/feed/ 0 http://www.biospace.com/news_story.aspx?StoryID=189131&full=1 http://www.biospace.com/news_story.aspx?StoryID=189131&full=1#comments Fri, 30 Jul 2010 00:00:00 +0000 BioSpace.com Featured News tag:feedrinse.com://85735f60bea784cdfbd7a59c29e95f0f , July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...]]> , July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...]]> http://www.biospace.com/news_story.aspx?StoryID=189131&full=1/feed/ 0 http://www.biospace.com/news_story.aspx?StoryID=189170&full=1 http://www.biospace.com/news_story.aspx?StoryID=189170&full=1#comments Fri, 30 Jul 2010 00:00:00 +0000 BioSpace.com Featured News tag:feedrinse.com://e78c94d7a8445124c3bcd944551a13cc

SAN DIEGO, CA--(Marketwire - July 30, 2010) - Lpath, Inc. (OTCBB: LPTN) was awarded a $3.0 million grant by the National Eye Institute's BRDG-SPAN Program to support Phase II clinical development of Lpath's iSONEP™ in treating exudative (or wet) AMD and possibly other ocular disorders.

Lpath...]]>

SAN DIEGO, CA--(Marketwire - July 30, 2010) - Lpath, Inc. (OTCBB: LPTN) was awarded a $3.0 million grant by the National Eye Institute's BRDG-SPAN Program to support Phase II clinical development of Lpath's iSONEP™ in treating exudative (or wet) AMD and possibly other ocular disorders.

Lpath...]]> http://www.biospace.com/news_story.aspx?StoryID=189170&full=1/feed/ 0 http://www.biospace.com/news_story.aspx?StoryID=189131&full=1 http://www.biospace.com/news_story.aspx?StoryID=189131&full=1#comments Fri, 30 Jul 2010 00:00:00 +0000 BioSpace.com Featured News tag:feedrinse.com://db9894f1b99cdeeac3813c0f710146f5 , July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...]]> , July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...]]> http://www.biospace.com/news_story.aspx?StoryID=189131&full=1/feed/ 0